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survival (p = 0.009 and 0.041, respectively).  Conclusions: Sin-
gle serum VEGF levels, at stable and exacerbated COPD, 
were not associated with clinically significant outcomes in 
COPD. Conversely, the VEGF course seems related to COPD 
prognosis.  © 2015 S. Karger AG, Basel 
 Introduction 
 Cigarette smoke is the most important cause of chron-
ic obstructive pulmonary disease (COPD) in the Western 
world. While most smokers handle this noxious agent 
without developing significant respiratory disease, the re-
maining genetically susceptible individuals progress to 
very different physiological and clinical changes, sub-
sumed under COPD. However, current diagnostic and 
therapeutic approaches largely ignore this heterogeneity 
 [1, 2] . To improve management, identification of specific 
COPD phenotypes remains of the greatest importance.
 Vascular endothelial growth factor (VEGF) covers a 
number of proteins, resulting from alternative splicing of 
a single VEGF gene. The transcription of VEGF is main-
ly controlled by hypoxia-inducing factor-1α, a hypoxia-
responding molecule  [3] . VEGF signaling was proposed 
to be associated with COPD development, COPD sever-
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 Abstract 
 Background: Impaired vascular endothelial growth factor 
(VEGF) signaling causes emphysema in animal models. In 
chronic obstructive pulmonary disease (COPD) patients, al-
terations in VEGF tissue expression have been observed. We 
hypothesize that circulating VEGF may be a biomarker to 
phenotype COPD patients.  Objective: The aim of this study 
was to investigate VEGF serum levels in stable and exacer-
bated COPD.  Methods: VEGF serum levels as well as param-
eters of short- and long-term outcome were assessed and 
analyzed in two COPD cohorts [PROMISE, n = 117; ProCOLD 
(PC), n = 191].  Results: VEGF serum levels at stable COPD 
were neither related to forced expiratory volume in 1 s nor 
to the Modified Medical Research Council dyspnea score, 
6-min walking distance or BODE index. There was no asso-
ciation between single VEGF levels and COPD exacerbation 
frequency or mortality at 1 and 2 years of follow-up. In PC an 
increase in VEGF over time (ΔVEGF) was associated with the 
exacerbation frequency as well as the 1- and 2-year hospital-
ization rate (p = 0.046, 0.009 and 0.006, respectively). Fur-
thermore, in PC ΔVEGF was associated with 1- and 2-year 
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ity, and distinct clinical and morphological COPD phe-
notypes such as emphysema. Cigarette smoke reduces the 
expression of VEGF receptor 2  [4] . Conditional knockout 
of the VEGF gene or VEGF receptor blockade results in 
lung cell apoptosis and emphysema  [5, 6] . In human 
lungs, a decreased VEGF expression was associated with 
emphysema  [7] . In contrast, an increased VEGF and 
VEGF receptor expression was observed in epithelial 
cells, alveolar macrophages and smooth muscle cells of 
COPD patients  [8] . It was proposed that VEGF is in-
creased in airways of COPD patients, while VEGF expres-
sion is decreased in the emphysematous parenchyma of 
COPD patients. These features may qualify VEGF as a 
clinically relevant marker for COPD. 
 The goal of this study was to characterize serum VEGF 
in stable and exacerbated COPD with regard to disease 
severity and outcome. To our knowledge, this is the first 
study investigating VEGF and outcome in COPD.
 Materials and Methods 
 Study Population 
 Herein, we report the results of two longitudinal COPD trials 
taking place at the University Hospital Basel, Switzerland. In both 
studies acute exacerbated COPD (AECOPD) was defined as an 
acute, sustained worsening of the COPD patient’s condition be-
yond normal day-to-day variation  [9] . Moderate AECOPD was 
defined as an AECOPD requiring systemic corticosteroids and/or 
antibiotics, whereas severe AECOPD required hospitalization 
 [10] . Mild AECOPDs were not evaluated. Both trials were ap-
proved by the institutional review board and registered as the Pro-
COLD study (PC; Ethics Committee of Basel 232/03, registration 
No. ISRCTN77261143) and as the PROMISE study (PM; Ethics 
Committee of Basel 295/07, registration No. ISRCTN99586989). 
Written informed consent was obtained from all patients.
 PC Study 
 The PC study was a single-center randomized controlled trial. 
From November 2003 to March 2005, patients hospitalized for 
acute exacerbations of COPD were recruited. Patients were re-
quired to (1) be at an age older than 40 years, (2) meet spirometric 
COPD criteria and (3) meet the severe AECOPD definition at 
study inclusion. Patients with immunosuppression, asthma, cystic 
fibrosis or radiographic infiltrates were excluded. A clinical assess-
ment, lung function and venous puncture were performed at ad-
mission, after 14–21 days and after 6 months. Outcome parameters 
were assessed until 2 years after study inclusion. The primary study 
objective was to improve antibiotic prescription based on procal-
citonin guidance as reported previously  [11] . Patients were ran-
domized at the index exacerbation to receive procalcitonin-guided 
or standard antibiotic therapy. Whereas procalcitonin guidance 
reduced antibiotic exposure, outcome did not differ in both groups. 
The evaluation of prognostic markers was a predetermined sec-
ondary end point of the study. VEGF serum levels 14–21 days after 
AECOPD were considered ‘stable COPD’. To assess the VEGF 
course in stable COPD, the difference of VEGF after 14–21 days 
and 6 months was used. For exacerbation, VEGF levels at admis-
sion were employed and compared to VEGF levels after 14–21 
days. 
 PM Study 
 From November 2008 to October 2011, stable COPD patients 
were recruited in the Pulmonary Department of the University 
Hospital Basel. Patients were required to: (1) fulfill GOLD (Global 
Initiative for Obstructive Lung Disease) grade II–IV criteria  [12] ; 
(2) be clinically stable for more than 4 weeks (based on the patients’ 
perception of cough, sputum and dyspnea); (3) be at least 40 years 
of age, and (4) have a smoking history of at least 10 pack-years. 
Patients were excluded if: (1) the main respiratory disorder was not 
COPD; (2) death was expected within 6 months; (3) the patient was 
immunosuppressed, or (4) a neuromuscular disorder prevented 
ambulation. The PM was a multicenter observational study per-
formed in 11 European centers. To guarantee fast processing of all 
blood specimens, only patients from the main study center (Uni-
versity Hospital Basel) were evaluated. A clinical assessment, lung 
function and venous puncture were performed at study inclusion 
and every 6 months for 2 years. Outcome parameters were assessed 
until 5 years after study inclusion. The primary objective was to 
identify novel markers of outcome in COPD. Therefore, the anal-
ysis of VEGF in PM represents a predefined study goal. VEGF se-
rum levels at study inclusion were considered ‘stable COPD’. To 
assess the VEGF course in stable COPD, the difference of VEGF at 
study inclusion and 1-year follow-up was used. Additional assess-
ments were performed at COPD exacerbation. 
 Determination of Serum VEGF Concentration 
 After venous puncture, blood samples were immediately cen-
trifuged at 4   °   C, the serum was stored at –80   °   C until further pro-
cessing. The samples were thawed on ice, and VEGF was instantly 
determined by an enzyme-linked immunosorbent assay (R&D 
Systems Inc., Minneapolis, Minn., USA). The used assay recog-
nizes VEGF165, VEGF121 and VEGF165b with a detection limit 
of 31.2 pg/ml as described by the manufacturer. All measurements 
were carried out in duplicate. 
 Statistical Analyses 
 Discrete variables are expressed as counts (with percentages) 
and continuous variables as means ± standard deviation. Compa-
rability between groups was analyzed by the χ 2 test, Fisher’s exact 
test, Student’s t test, the Mann-Whitney U test or Kruskal-Wallis 
test as appropriate. Comparability within groups was analyzed by 
the paired t test or Wilcoxon’s signed-rank test. Pearson’s and 
Spearman’s correlations were used to measure the relationship be-
tween two continuous variables. The Kolmogorov-Smirnov test 
was applied to test normal distribution. To assess whether a change 
in COPD severity, i.e. progressing respiratory disease, is related to 
a change in VEGF levels, ΔVEGF was associated with outcome 
parameters. Due to the nonnormal distribution of serum VEGF 
concentrations, the VEGF course was calculated using log-trans-
formed parameters. ΔVEGF was defined as: logVEGF at base-
line – logVEGF after 1 year (PM study) and logVEGF after 2–3 
weeks – logVEGF after 6 months (PC study). All tests were 2-tailed, 
and a p value <0.05 was defined as significant. Data were analyzed 
using the Statistical Package for Social Sciences (SPSS Inc., Chi-
cago, Ill., USA; version 20 for Mac).
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 Results 
 Baseline characteristics of both study cohorts are pre-
sented in  table 1 . 
 Absolute VEGF Levels in Stable COPD 
 Age and gender were not related to VEGF serum levels 
in any of the trials (PM: p = 0.8 and 0.08, respectively; PC: 
p = 0.7 and 0.4, respectively). In the PC cohort, VEGF 
levels were elevated in patients with cardiac disease (mean 
± standard deviation; 490 ± 333 vs. 423 ± 228 pg/ml, p = 
0.011) and diabetes (536 ± 288 vs. 439 ± 274 pg/ml, p = 
0.033). Conversely, in the PM trial this difference was not 
evident (p = 0.9 and 0.9, respectively). There was no dif-
ference in VEGF levels regarding other comorbidities and 
medication ( table 1 ). Measures of COPD severity, such as 
forced expiratory volume in 1 s (FEV 1 ) and GOLD grade, 
were not related to VEGF levels at stable COPD (PM: p = 
0.12 and 0.3, respectively; PC: p = 0.14 and 0.7, respec-
tively). Similarly, GOLD stage, Modified Medical Re-
search Council dyspnea score, 6-min walking distance 
and BODE index were not associated with VEGF (PM: 
p = 0.3, 0.7, 0.4 and 0.16, respectively). VEGF levels at dif-
ferent study visits in PC and PM are presented in  table 2 .
 Individual VEGF levels at stable COPD were not as-
sociated with the number of subsequent AECOPDs per 
year and mortality (PM: moderate and severe AECOPDs 
per year p = 0.7, 2-year mortality p = 0.8, 5-year mortal-
ity p = 0.3; PC: moderate and severe AECOPD number
p = 0.7, 1-year mortality p = 0.6, 2-year mortality p = 0.6; 
 table 3 ). 
 ΔVEGF Level in Stable COPD 
 Several associations between the VEGF course and 
outcome were identified in stable COPD. In the PM trial, 
the ΔVEGF was similar regarding the rate of AECOPDs 
(moderate and severe), severe AECOPDs, 2-year mortal-
ity and 5-year mortality (p = 0.6, 0.9, 0.3 and 0.9, respec-
tively;  fig. 1 ). In contrast, in the PC trial, the ΔVEGF was 
different with respect to exacerbation rate, 1- and 2-year 
hospitalization rate (p = 0.046, 0.009 and 0.006, respec-
tively). Similarly, the 1- and 2-year survival was decreased 
in patients with a reduced ΔVEGF (PC: p = 0.009 and 
0.041, respectively). 
 VEGF at AECOPD 
 VEGF serum levels at AECOPD (moderate and se-
vere) were similar to stable COPD VEGF levels in the PM 
as well as in the PC trial (p = 0.08 and p = 0.6, respective-
ly;  fig. 2 ). There was a positive correlation of VEGF and 
 Table 1.  Demographic characteristics of the two study cohorts
PM cohort
(n = 117)
PC cohort
(n = 191)
Age, years 67 ± 11 70 ± 10
Gender female 34 (29) 89 (47)
Height, cm 169 ± 8
Weight, kg 75 ± 21
BMI 26 ± 7
Comorbidities
Cardiac disease 34 (29) 83 (44)*
Diabetes mellitus 19 (16) 21 (11)*
Renal insufficiency 18 (15) 15 (8)
Malignancy 9 (8) 25 (13)
Osteoporosis 15 (13) 23 (12)
Arterial hypertension 67 (57) 44 (23)
Liver disease 12 (10)
Pulmonary hypertension 19 (16)
Depression 17 (15)
Adjusted Charlson score 4.7 ± 2.4
COPD history
Current smoker 40 (34) 86 (45)
Pack-years smoked 51 ± 25 45 ± 28
COPD duration, years 5.8 ± 2.1 10 ± 7
Lung function parameters
FEV1, % predicted 50 ± 18 45 ± 20a
FVC, % predicted 80 ± 18* 71 ± 21a
FEV1/FVC, % 47 ± 15 50 ± 15a
COPD assessment
GOLD grade 1 – 15 (8)
grade 2 56 (48) 44 (23)
grade 3 42 (36) 66 (35)
grade 4 18 (15) 52 (27)
GOLD stage A 13 (11)
stage B 35 (30)
stage C 3 (3)
stage D 63 (54)
MMRC dyspnea score 1.7 ± 1.1
6-min walking distance, m 372 ± 109
BODE index 2.8 ± 2.2
Bronchitic phenotype 67 (57)
COPD therapy at study inclusion
Inhaled anticholinergics 81 (69) 97 (51)
Inhaled β2-agonists 94 (80) 163 (85)
Inhaled steroids 100 (85) 140 (73)
Systemic steroids 11 (9) 59 (31)
Theophylline 7 (6) 21 (11)
Long-term oxygen therapy 19 (16) 27 (14)
 Discrete variables are expressed as counts with percentages in 
parentheses and continuous variables as means ± standard devia-
tion. All parameters were associated with VEGF serum levels us-
ing Pearson’s correlation, Spearman’s correlation, Student’s t test, 
the Mann-Whitney U test and Kruskal-Wallis test as appropriate. 
* p < 0.05: significant association with VEGF at stable state. BMI 
= Body mass index; FEV1 = forced expiratory volume in 1 s; FVC 
= forced vital capacity; MMRC = Modified Medical Research 
Council. 
a Presented lung function parameters of the PC study were ob-
tained 14–21 days after study inclusion.
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COPD duration as well as VEGF and leukocyte count 
(PC: p = 0.046 and 0.005, respectively) at AECOPD. Fur-
thermore, patients who presented with an increased 
amount of sputum had elevated VEGF levels (PC: p = 
0.045). Neither VEGF levels at AECOPD nor the VEGF 
course after AECOPD were related to measures of COPD 
severity or outcome. VEGF levels at AECOPD did not dif-
fer regarding exacerbation frequency, hospitalization and 
survival.
 Discussion 
 Herein we report that single VEGF serum levels in sta-
ble and exacerbated COPD are not associated with mark-
ers of disease severity or outcome. However, increasing 
VEGF levels in patients with stable COPD might be re-
lated to poor prognosis. 
 An association between VEGF and airway obstruction 
was reported previously. Serum VEGF and FEV 1 corre-
lated positively in 30 patients with stable COPD  [13] . 
However, there was no difference in VEGF between stable 
COPD patients and healthy subjects  [13, 14] . Elevated 
VEGF serum levels in COPD patients were reported in 2 
other trials  [15, 16] . Another study demonstrated elevated 
VEGF serum levels in patients with mild COPD only, 
though negatively correlating with FEV 1  [17] . We did not 
observe any association between single VEGF levels and 
established markers of COPD severity. In both trials VEGF 
levels did not correlate with FEV 1 . Furthermore, there was 
no association between VEGF and diffusion capacity, 
walking distance, GOLD grade (1, 2, 3, 4), GOLD stage (A, 
B, C, D), BODE index and symptom score. Data of VEGF 
levels at COPD exacerbations are inconsistent. Whereas 
elevated serum VEGF levels were reported  [13, 18] , other 
studies did not observe this difference  [19] . We compared 
 Table 2. VEGF levels at stable and exacerbated COPD
PM cohort  PC cohort
baseline
(stable)
follow-up AECOPD baseli ne
(AECOPD)
follow-up
14 – 21 days 
follow-up
6 months
n = 117 n = 89 n = 30 n = 173 n = 161 n = 148
322 ± 341 183 ± 267 1,019 ± 1,550 438 ± 274 437 ± 277 436 ± 259
 Table 3.  Outcome measures in the two study cohorts
Outcome PM cohort
(n = 117)
PC cohort
 (n = 191)
measure p  measure p
Hospitalization of any cause within 1 year 66 (35) 0.9
Hospitalization of any cause within 2 years 92 (48) 0.3
AECOPDs (moderate and severe) per year
(within 2 years) 0.9 ± 1.3 0.7 2.1 ± 1.9 0.7
Severe AECOPDs per year (within 2 years) 0.2 ± 0.4 0.7
Frequent exacerbator (≥2 AECOPDs/year) 20 (17) 0.6 97 (51) 0.6
1-year all-cause mortality 12 (6) 0.6
2-year all-cause mortality 13 (11) 0.8 37 (19) 0.6
5-year all-cause mortality 38 (33) 0.3
 Discrete variables are expressed as counts with percentages in parentheses and continuous variables as means 
± standard deviation. All parameters were associated with VEGF serum levels using Pearson’s correlation, Spear-
man’s correlation, Student’s t test, the Mann-Whitney U test and Kruskal-Wallis test as appropriate. p values as 
assessed by the association with VEGF.
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VEGF serum levels in stable and exacerbated COPD with-
in patients. However, in both trials VEGF levels at COPD 
exacerbation did not differ from stable COPD. 
 Similarly, VEGF levels in respiratory secretions are 
conflicting. Most studies indicate that VEGF in sputum 
or epithelial lining fluid of central and peripheral airways 
is lower in COPD and decreases with increasing severity 
 [14, 20, 21] . Controversially, elevated sputum VEGF lev-
els were observed in COPD patients, negatively correlat-
ing with FEV 1  [19] . Kanazawa et al.  [22] reported elevat-
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 Fig. 1. Course of VEGF serum levels during stable COPD in association with outcome. ΔVEGF levels of the PM 
( a–c ) and PC trials ( d–h ) are presented with regard to important COPD outcome measures. Comparability be-
tween groups was analyzed by Student’s t test or the Mann-Whitney U test. 
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ed VEGF sputum levels in chronic bronchitis compared 
to normal controls, negatively correlating with FEV 1 , 
whereas VEGF sputum levels were reduced in emphyse-
ma positively correlating with FEV 1 . Herein, we did not 
identify a difference in VEGF levels regarding chronic 
bronchitis or diffusion capacity, a marker of emphysema. 
This is in line with results of a previous trial observing 
similar VEGF levels in patients with and without emphy-
sema, as defined by high-resolution computed tomogra-
phy  [23] .
 In contrast to the cross-sectional design of previous 
studies, we performed a longitudinal study, allowing the 
assessment of short- and long-term outcome as well as the 
change of serum levels over time. VEGF serum levels at 
stable or exacerbated COPD were not associated with the 
COPD exacerbation frequency and mortality. However, 
in one study the VEGF course during stable COPD was 
associated with clinically relevant outcomes in COPD. In-
terestingly, an increase in VEGF levels was related to poor 
outcome. In line with these results we identified elevated 
VEGF levels with increasing COPD duration. Three ar-
guments may explain this finding. As mentioned above, 
increased VEGF levels may reflect the bronchitic pheno-
type of COPD, associated with more and severer exacer-
bations  [24] . The observation that increased sputum pro-
duction at AECOPD is associated with elevated VEGF 
levels supports this notion. Second, serum VEGF is not 
necessarily related to VEGF levels of sputum. Other com-
partments of the COPD lung, such as alveoli and pulmo-
nary vasculature may contribute to elevated VEGF serum 
levels, but not to VEGF in airway secretions. Third, al-
though most studies revealed decreasing VEGF levels in 
sputum and airways with increasing disease severity, con-
trary reports challenge these findings  [19] . Several trials 
reported elevated serum VEGF in COPD, some of them 
negatively correlating with FEV 1 , i.e. positively correlat-
ing with COPD severity  [13, 15, 16] . Moreover, since the 
main stimulant of VEGF is hypoxia, via hypoxia-induc-
ible factor  [3] , an increase in VEGF serum levels in se-
verer disease seems plausible. This may also explain the 
worse outcome in patients with increasing VEGF levels. 
 To our knowledge this is the largest evaluation of 
VEGF in COPD so far. Nevertheless, several limitations 
merit consideration. First, VEGF has a very short half-life 
prone to measurement errors. To overcome this bias, 
blood samples were centrifuged cool and frozen immedi-
ately after venous puncture. To ensure optimal quality 
only blood samples of a single center were used. Second, 
we do not know whether VEGF serum levels adequately 
reflect VEGF levels in alveoli and airways. In any case, the 
determination of VEGF in bronchoalveolar lavage fluid 
or sputum tends to be more tedious and would hardly be 
useful in the clinical routine. There exist several differ-
ences regarding the two study cohorts. Whereas the PC 
study included only patients with exacerbated COPD, in 
the PM trial patients were included exclusively at stable 
COPD. Thus, PC patients may have been more prone to 
recurring exacerbations and inflammation  [25, 26] . 
Moreover, in the PC we considered stable patients 14–21 
days after exacerbation; however, a proportion may not 
have reached clinical stability, possibly affecting the re-
sults. It is noteworthy that VEGF levels in the PC were 
very similar in stable and exacerbated COPD, whereas in 
the PM there was a trend to higher VEGF levels during 
exacerbation. Importantly, in the PC an increase in VEGF 
levels was associated with poor outcome. Finally, we can-
not rule out that the VEGF course, and the associated 
clinical outcome, does not directly reflect COPD activity 
2
1
0
©
OR
J9
(*
)
$
(&
2
3'
²
V
WD
EO
H
&2
3'

©
OR
J9
(*
)
$
(&
2
3'
²
V
WD
EO
H
&2
3'

²
²
2
1
0
²
²
a
S 
Q  b
S 
Q 
 Fig. 2. Difference of VEGF serum levels be-
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but rather the severity of associated comorbidities. In any 
case, VEGF change over time was significantly associated 
with all-cause mortality. Further studies would have to 
assess the influence of specific comorbidities such as car-
diovascular disease and malignancy in the levels of this 
biomarker. Strategies combining several disease markers 
will be necessary to address the complexity of COPD  [27, 
28] . Novel tools such as the omics approaches are promis-
ing for stratifying clinically relevant COPD phenotypes 
 [29] .
 We conclude that a single VEGF serum level does not 
reflect COPD severity and outcome, neither at the stable 
state nor at exacerbation. Thus, single VEGF serum levels 
are unlikely to be a clinically relevant marker in COPD. 
However, increasing VEGF levels might identify patients 
with a poorer prognosis. This finding warrants future in-
vestigations. 
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